Search Results for: covid-19
Articles
New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential
The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M have collaborated to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2….
Biosight Completes Enrollment in Phase 2b Study for First-Line Acute Myeloid Leukemia Therapy
Biosight Ltd. recently announced it has completed enrollment in the company’s ongoing Phase 2b trial evaluating aspacytarabine (BST-236) as a...Altimmune Announces New Preclinical Data for AdCOVID Demonstrating Sterilizing Immunity After a Single Intranasal Dose
Altimmune, Inc. recently announced positive results from a preclinical study of AdCOVID in a SARS-CoV-2 challenge model of infection. In...EXECUTIVE INTERVIEW - Lexaria Bioscience Corp.: Stretching Its Legs
John Docherty, President of Lexaria, discusses how the company’s recent uplist to the NASDAQ has resulted in its largest capital injection to date, which will allow it to focus on preclinical and clinical testing programs for DehydraTECH formulations across three main areas of interest.
INJECTABLES MANUFACTURING - Manufacturing Injectable Devices: Why Modern Means Modular
Raffaele Pace, MMe, MBA, reviews how today’s drug delivery devices must be more mobile, less intrusive, and simpler than ever before – all while remaining cost competitive.
Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm
Australian clinical-stage drug development company Noxopharm Limited recently announced that in a cohort of 18 patients with moderately severe cases of...CordenPharma Colorado Expands Lipid Excipients Purfication
In response to the COVID-19 pandemic, mRNA (messenger RNA) vaccines have catapulted to center stage of the pharmaceutical and biotechnology...AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis
AzurRx BioPharma, Inc. recently announced it has entered into an agreement with PPD, Inc. for its planned Phase 1b/2a clinical trial evaluating proprietary formulations of micronized….
Calixar Invests in Pipeline of Highly Druggable Membrane Protein Targets & Native Antigens
Calixar recently announced its €1M ($1.2M) investment in a new pipeline of complex therapeutic targets and native antigens of high...Cidara Therapeutics Announces Agreement With Janssen to Develop & Commercialize AVCs for the Prevention & Treatment of Influenza
Cidara Therapeutics, Inc. recently announced it has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, Inc. to develop and commercialize….
